PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION as well	see Form PCT/ISA/220 I as, where applicable, Item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/GB2004/001128	17/03/2004	18/03/2003
Applicant		
•		
MILNER, JO		
This international Search Report has been according to Article 18. A copy is being tre	n prepared by this International Searching Authorsmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consists		
X It is also accompanied by	a copy of each prior art document cited in this	report
language in which it was filed, unl	nternational search was carried out on the basess otherwise indicated under this item.	
this Authority (Rul	e 23.1(b)).	ation of the international application furnished to
b. X With regard to any nucleo	tide and/or amino acld sequence disclosed	in the International application, see Box No. I.
2. X Certain claims were four	nd unsearchable (See Box II).	
S. X Unity of invention is lack	tin g (see Box III).	
4. With regard to the title,		
X the text is approved as sul		
the text has been establish	ned by this Authority to read as follows:	
		;
P. 1879 and so the abound		•
5. With regard to the abstract, the text is approved as sub	mitted by the applicant.	
	and according to Pula 38 2/h) by this Authority	as it appears in Box No. IV. The applicant
may, within one month from	n the date of mailing of this international search	h report, submit comments to this Authority.
With regards to the drawings,		
	blished with the abstract is Figure No	· .
X as suggested by the		
	Authority, because the applicant failed to sugg	gest a figure.
	Authority, because this figure better character	
b. none of the figures is to be	published with the abstract.	

Int nat Application No Pur/ uB2004/001128

	·		.,
A. CLASSI IPC 7	FICATION OF SUBJECT MATTER C07K14/47 C12N15/11 A61K48/0	0 A61P35/00	
According to	o International Patent Classification (IPC) or to both national classific	ation and IPC	
	SEARCHED		
Minimum do IPC 7	ocumentation searched (classification system followed by classification CO7K C12N A61K	on symbols)	
Documenta	tion searched other than minimum documentation to the extent that s	uch documents are included in the fields se	erched
Electronic d	ata base consulted during the International search (name of data base	se and, where practical, search terms used)
EPO-In	ternal, BIOSIS, WPI Data, PAJ		
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with indication, where appropriate, of the reli	evani passages	Relevant to claim No.
X	CIOCA DANIEL P ET AL: "RNA inter is a functional pathway with ther potential in human myeloid leukem lines."	apeutic	1-4, 7-11, 15-18
Y	CANCER GENE THERAPY, vol. 10, no. 2, February 2003 (20 pages 125-133, XP002293680 ISSN: 0929-1903 page 126, left-hand column, last - right-hand column, paragraph 1 figures 1,3 page 132, left-hand column, parag	paragraph	19
		-/	
X Furt	ther documents are listed in the continuation of box C.	Patent family members are listed	n ennex.
"A" docum consi "E" earlier filing "L" docum which citatio "O" docum other "P" docum later t	ategories of cited documents: ant defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another an or other special reason (as specified) sent referring to an oral discrosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	T later document published after the Inter or priority date and not in conflict with cited to understand the principle or the Invention of the Cannot be considered novel or cannot be considered novel or cannot with the cannot be considered novel or cannot be considered to involve an in document of particular relevance; the cannot be considered to involve an in document is combined with one or morents, such combined with one or morents, such combined with one or in the art. *8* document member of the same palent.	the application but alony underlying the statemed invention the considered to current is taken alone statemed invention ventive step when the re other such docu- us to a person skilled family
2	26 October 2004		0 8. 11. 2004
Name and	mailing address of the ISA European Palent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (431-70) 340-2040. Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer ALCONADA RODRIGUE	Z

Im Jonal Application No Pul/GB2004/001128

0.0	<u> </u>	PC1/GB2004/001128				
Category *	(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT alegory * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.					
	Challes of Country, West Water Country, Williams Country Count					
x	FUTAMI TAKASHI ET AL: "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2." NUCLEIC ACIDS RESEARCH. SUPPLEMENT (2001) 2002, no. 2, 2002, pages 251-252, XP002264267	1-4, 7-11, 15-20				
Y	abstract	19				
X	WO 02/055692 A (VORNLOCHER HANS-PETER; LIMMER STEFAN (DE); RIBOPHARMA AG (DE); GEICK) 18 July 2002 (2002-07-18) page 5, lines 17-26 page 7, lines 18-22 page 3, lines 19-33 page 6, lines 10-26	1,2, 5-10,13, 15-18				
Y	GAUTSCHI O ET AL: "ACTIVITY OF A NOVEL BCL-2/BCL-XL-BISPECIFIC ANTISENSE OLIGONUCLEOTIDE AGAINST TUMORS OF DIVERSE HISTOLOGIC ORIGINS" JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 93, no. 6, 21 March 2001 (2001-03-21), pages 463-471, XP009003270 ISSN: 0027-8874 figures 2-4	19				
A	US 6 414 134 B1 (REED JOHN C) 2 July 2002 (2002-07-02) the whole document					
P,X	WO 03/070969 A (MCSWIGGEN JAMES; BEIGELMAN LEONID (US); SIRNA THERAPEUTICS INC (US)) 28 August 2003 (2003-08-28) page 7, lines 17-20; examples 4-10; tables II,III	1-5, 7-11,13, 15-20				
Ρ,Χ	WACHECK VOLKER ET AL: "Small interfering RNA targeting Bcl-2 sensitizes malignant melanoma." OLIGONUCLEOTIDES, vol. 13, no. 5, October 2003 (2003-10), pages 393-400, XP001189796 ISSN: 1545-4576 page 394, right-hand column, paragraph 2; figures 4,5	1-4, 7-11, 15-18				
	-/					

In Ional Application No

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Retevant to claim No.				
Ρ, Χ	JIANG MING ET AL: "Bc1-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells." GENES AND DEVELOPMENT, vol. 17, no. 7, 1 April 2003 (2003-04-01), pages 832-837, XP002293683 ISSN: 0890-9369 the whole document	1-4, 7-12, 15-20				
Ρ,Χ	CAO XIAOBO X ET AL: "A short-interfering RNA (siRNA) duplex targeted to BCL-XL significantly reduces BCL-XL expression and enhances response to chemotherapy in mesothelioma." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07), page 1098, XP001182915 & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003 ISSN: 0197-016X abstract	1,2, 5-10, 13-20				
P,X	ZENDER L ET AL: "Small interfering RNA (siRNA) and antisense oligonucleotides (ASO) for reversion of chemotherapy resistance in hepatoma cells." JOURNAL OF HEPATOLOGY, vol. 38, no. Supplement 2, April 2003 (2003-04), page 107, XP002301756 & 38TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; INSTANBUL, TURKEY; MARCH 29-APRIL 01, 2003 ISSN: 0168-8278 abstract	1,2, 5-10,13, 15-18				
Ρ,Χ	WALTEMATHE M ET AL: "Essential role for bcl-xl as an antiapoptotic factor in TRAIL mediated apoptosis of hepatocytes during viral infection." JOURNAL OF HEPATOLOGY, vol. 38, no. Supplement 2, April 2003 (2003-04), page 107, XP002301757 & 38TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; INSTANBUL, TURKEY; MARCH 29-APRIL 01, 2003 ISSN: 0168-8278 abstract	1,2, 5-10,13, 15-18				
Ρ,χ	WO 03/040366 A (HAREL-BELLAN ANNICK; DAUTRY FRANCOIS (FR); AIT-SI-ALI SLIMANE (FR); C) 15 May 2003 (2003-05-15) claims 14,15,28,31	1,2,5, 7-10,13, 15-18				

Inte nal application No.

PCT/GB2004/001128

Box	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of Item 1.b of the first sheet)
1.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ntion, the international search was carried out on the basis of:
	a.	type of material X a sequence listing table(s) related to the sequence listing
	b.	format of material X in written format X in computer readable form
	c.	contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purpose of search
2.	X	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addit	tional comments:

national application No. PCT/GB2004/001128

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-7, as far as relating to an in vivo method, and claims 15 and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box ill Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)
This international Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search lees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1,2,7-10, 15-20 (in part) and 3, 4,11, 12 (complete)

A siRNA construct which is homologous to the Bcl-2 mRNA; method of regulating apoptosis and of treating dieseases associated with inappropriate apoptosis by introducing said siRNA into a cell.

2. claims: 1,2,7-10, 15-20 (in part) and 5, 6, 13, 14 (complete)

As invention 1 but relating to an siRNA construct which is homologous to the Bcl-XL mRNA.

inal Application No JB2004/001128

			, JB2004/001128		
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02055692	A	18-07-2002	DE CA WO EP ES JP US ZA	10100586 C1 2432341 A1 2432350 A1 02055692 A2 02055693 A2 1349927 A2 1352061 A2 2204360 T1 2004519457 T 2004519458 T 2004001811 A1 2004175703 A1 200304500 A	11-04-2002 18-07-2002 18-07-2002 18-07-2002 18-07-2002 08-10-2003 15-10-2003 01-05-2004 02-07-2004 02-07-2004 01-01-2004 09-09-2004 18-11-2003
US 6414134	B1	02-07-2002	US US CA EP JP JP WO US	6040181 A 5831066 A 2172153 A1 0722342 A1 2001505401 T 2003026609 A 9508350 A1 5734033 A	21-03-2000 03-11-1998 30-03-1995 24-07-1996 24-04-2001 29-01-2003 30-03-1995 31-03-1998
WO 03070969	A	28-08-2003	CAAAAAAAAPPPPPPPPPPPBBBBBBOOOOOOOOOOOOOO	2455447 A1 2455506 A1 2456444 A1 2457528 A1 2457528 A1 2457528 A1 2457528 A1 2463595 A1 2471421 A1 1432724 A1 1463842 A1 1465910 A2 1442143 A2 1442143 A2 1448590 A2 1448590 A2 1448580 A2 1448580 A2 1430157 A2 1458741 A2 1436314 A2 1423406 A2 2396864 A 2396155 A 2396165 A 2397062 A 2397818 A 03072590 A1 03072704 A2 03072705 A2 03070881 A2 03070881 A2 03070886 A2 03070886 A2 03070886 A2 03070886 A2	12-09-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2004 06-10-2004 13-10-2004 02-06-2004 25-08-2004 25-08-2004 22-09-2004 14-07-2004 02-06-2004 07-07-2004 16-06-2004 14-07-2004 04-08-2004 20-06-2004 14-07-2004 04-08-2004 14-07-2004 04-09-2003 04-09-2003 04-09-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003 28-08-2003

In: onal Application No
P..., 3B2004/001128

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03070969	A		WO	03070887	A2	28-08-2003
			WO	03070888	A2	28-08-2003
			WO	03070966	A2	28-08-2003
			WO	03070744	A1	28-08-2003
WO 03040366	Α	15-05-2003	FR	2832154	A1	16-05-2003
			FR	2838442	A1	17-10-2003
			CA	2466773	A1	15-05-2003
			EP	1453962	A2	08-09-2004
			WO	03040366	A2	15-05-2003